The US FDA has approved Medtronic’s 780G for use with rapid-acting insulin and with Abbott’s type 2 diabetes-specific sensor.

The 510(k) decision clears the device for use with ultra-rapid-acting insulins from Eli Lilly and Novo Nordisk.

GALWAY, Ireland, Dec. 2, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the broad U.S. commercial launch of the MiniMed™ 780G system integrated ...

Medtronic (NYSE:MDT) has recalled its SonarMed Airway acoustic sensors, which are used with ventilators to provide real-time airway monitoring information to clinicians. According to the FDA’s website ...

Beneficiaries of Medicare and Medicare Advantage can now obtain the MiniMed 780G system combined with the Instinct sensor.

Medtronic (NYSE:MDT) announced an agreement to acquire CathWorks, aiming to add AI-powered coronary artery disease tools to ...

Medtronic has commercially launched its MiniMed 780G system in the US, now integrated with Abbott’s Instinct sensor. The Instinct sensor utilises Abbott’s continuous glucose monitoring (CGM) ...

The FDA has elevated a recall from Medtronic over neonatal intensive care systems that monitor the airways of intubated newborns, due to sensors that may fail to detect obstructions. The NICU safety ...

Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that ...